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BACKGROUND
RESULTS
DISCUSSION
• Procedures & Participants:
• Retrospective study of 81 PBT patients at a Mid-Atlantic 
urban academic medical cancer center.
• Inclusion criteria were as follows: (1) confirmed PBT 
diagnosis via histopathology; (2) a minimum of 2 weeks 
post-surgical resection or biopsy (if applicable); and (3) 
English speaking. 
• Mage = 49 yrs., 50.6% Men, 96.3% White
• Data obtained from neuropsychological evaluations and 
medical record
• Neuropsychological Measures: 
• Test of Premorbid Functioning (TOPF)8
• MMSE-21
• Impairment defined as a score <27
• RBANS7
• Impaired performance defined as at least one index 
score ≥1 standard deviation below TOPF10
• The Mini-Mental State Examination (MMSE) is regularly used to 
screen for cognitive impairment and is reported as the second 
most used cognitive screener by physicians.1-2
• However, the MMSE is less sensitive to mild neurocognitive 
disorders (mNCD) such as that commonly seen among primary 
brain tumor (PBT) patients.3
• In PBT patients, the MMSE has been shown to have dismal 
sensitivity to cognitive impairment and poor sensitivity to 
change.4-5
• Comparison between the MMSE, MoCA, and a comprehensive 
neuropsychological battery revealed extremely poor sensitivity 
of the MMSE to mNCD and that no cut score for either screener 
was adequate for optimal sensitivity and specificity.6
• More comprehensive screening tools, such as the Repeatable 
Battery for the Assessment of Neuropsychological Status 
(RBANS), may be more suitable for use with PBT patients.7
• Significantly fewer patients were identified as impaired on the 
MMSE-2 (33%; n = 27) than on the RBANS (52%; n=64 ; χ2=17.57,
p=<.01). 
• Compare the proportion of impairment indicated on both the 
MMSE-2 and RBANS in PBT patients and conduct preliminary 
analysis of the sensitivity and specificity of the MMSE-2 to the 
level of cognitive impairment identified on the RBANS.
• Medical practitioners should consider alternative screeners and 
rely less heavily on the MMSE-2 within neuro-oncology clinics 
given the relative rates of indicated impairment and preliminary 
evidence regarding the MMSE-2’s sensitivity to the level of 
cognitive impairment detected on the RBANS. 
• While it appears that the MMSE-2 accurately categorizes those 
with true cognitive impairment as impaired (i.e., true positives), 
results suggest that an individual scoring >27 on the MMSE-2 
is still rather likely to be categorized as impaired on other, more 
comprehensive screeners (i.e., false negatives). 
• More comprehensive screeners such as the RBANS may have 
greater clinical utility in screening for cognitive impairment 
among PBT patients, particularly if the objective of screening is 
to minimize false negatives and increase access to additional 
supports. 
• Future studies should assess the relative utility of screeners 
among PBT patients by using a comprehensive 
neuropsychological test battery to assess sensitivity and 
specificity to a diagnosis of mNCD. 
• Additionally, feasibility and acceptability research is needed to 
assess if use of the RBANS in neuro-oncology clinics for 
screening is a possible when a neuropsychologist is not part of 
the integrated care team.
• In sum, if clinicians rely solely on the MMSE-2, as is common 
practice in many medical centers, patients who could benefit 
from additional services may go undetected. 
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• When evaluating the sensitivity of the MMSE-2 to a “positive screen”
on the RBANS, defined as one or more impaired indices, sensitivity
was 38.2% (95% CI = 26.71% to 50.82%) and specificity was 92.3%
(CI = 63.97% to 99.81%).
• The positive predictive value of the MMSE-2 was 96.3% (CI =
79.43% to 99.43%). The negative predictive value was 22.2% (CI =
18.29% to 26.72%). Accuracy of the MMSE-2 was 46.91% (CI =
35.73% to 58.33%).
Data Analytic Plan:
• Frequencies determined proportion of impairment for each 
screener. Chi-square analyses indicated difference between 
proportions.
• Binary logistical regression and ROC analysis assessed 
specificity and sensitivity for the MMSE-2 to detect the level of 
impairment identified on a “positive screen” of the RBANS. 
METHODS cont.
Medical Characteristics N (%)
Tumor Grade
Low 28 (34.6%)
High 46 (56.8%)
Unknown 7 (8.6%)
Therapy
Resection 62 (76.5%)
Radiation 47 (58.0%)
Chemotherapy 47 (58.0%)
Seizure History 
History 40 (49.4%)
Ongoing 12 (15.8%)
Current Anticonvulsant 35 (42.3%)
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